Erschienen in:
01.02.2008 | Correspondence
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy
verfasst von:
Kalman Kovacs, Bernd W. Scheithauer, Matilde Lombardero, Roger E. McLendon, Luis V. Syro, Humberto Uribe, Leon D. Ortiz, Luis C. Penagos
Erschienen in:
Acta Neuropathologica
|
Ausgabe 2/2008
Einloggen, um Zugang zu erhalten
Excerpt
Temozolomide, an alkylating imidazol tetrazine derivative, inhibits DNA replication and is used successfully in the management of patients with gliomas and other malignancies [
5,
12]. Recent studies showed the drug to be effective in patients with pituitary carcinoma and aggressive pituitary adenoma [
1,
2,
7,
10,
14]. …